Chaste: a test-driven approach to software development for biological modelling J Pitt-Francis, P Pathmanathan, MO Bernabeu, R Bordas, J Cooper, ... Computer Physics Communications 180 (12), 2452-2471, 2009 | 300 | 2009 |
An integrative computational model for intestinal tissue renewal IMM Van Leeuwen, GR Mirams, A Walter, A Fletcher, P Murray, J Osborne, ... Cell proliferation 42 (5), 617-636, 2009 | 180 | 2009 |
Crypt dynamics and colorectal cancer: advances in mathematical modelling IMM Van Leeuwen, HM Byrne, OE Jensen, JR King Cell proliferation 39 (3), 157-181, 2006 | 125 | 2006 |
Sirtuins and p53 I van Leeuwen, S Lain Advances in cancer research 102, 171-195, 2009 | 92 | 2009 |
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage MJGW Ladds, IMM Van Leeuwen, CJ Drummond, S Chu, AR Healy, ... Nature communications 9 (1), 1107, 2018 | 89 | 2018 |
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy B Rao, IMM van Leeuwen, M Higgins, J Campbell, AM Thompson, ... Oncotarget 1 (7), 639, 2010 | 79 | 2010 |
Elucidating the interactions between the adhesive and transcriptional functions of β-catenin in normal and cancerous cells IMM van Leeuwen, HM Byrne, OE Jensen, JR King Journal of theoretical biology 247 (1), 77-102, 2007 | 75 | 2007 |
Modelling microbial adaptation to changing availability of substrates BW Brandt, FDL Kelpin, IMM van Leeuwen, SALM Kooijman Water research 38 (4), 1003-1013, 2004 | 69 | 2004 |
A general model for multiple substrate biodegradation. Application to co-metabolism of structurally non-analogous compounds BW Brandt, IMM van Leeuwen, SALM Kooijman Water research 37 (20), 4843-4854, 2003 | 67 | 2003 |
Towards a multiscale model of colorectal cancer IMM Van Leeuwen, CM Edwards, M Ilyas, HM Byrne World journal of gastroenterology: WJG 13 (9), 1399, 2007 | 66 | 2007 |
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells IMM van Leeuwen, B Rao, MCC Sachweh, S Laín Cell cycle 11 (9), 1851-1861, 2012 | 62 | 2012 |
Mechanism-specific signatures for small-molecule p53 activators IMM van Leeuwen, M Higgins, J Campbell, CJ Brown, AR McCarthy, ... Cell cycle 10 (10), 1590-1598, 2011 | 60 | 2011 |
Dynamic energy budget approaches for modelling organismal ageing IMM van Leeuwen, J Vera, O Wolkenhauer Philosophical Transactions of the Royal Society B: Biological Sciences 365 …, 2010 | 60 | 2010 |
Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2 IMM van Leeuwen, M Higgins, J Campbell, AR McCarthy, MCC Sachweh, ... Molecular cancer therapeutics 12 (4), 471-480, 2013 | 54 | 2013 |
Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner AR McCarthy, MCC Sachweh, M Higgins, J Campbell, CJ Drummond, ... Molecular cancer therapeutics 12 (4), 352-360, 2013 | 47 | 2013 |
SysBioMed report: advancing systems biology for medical applications O Wolkenhauer, D Fell, P De Meyts, N Blüthgen, H Herzel, N Le Novere, ... IET systems biology 3 (3), 131-136, 2009 | 47 | 2009 |
Systems biologists seek fuller integration of systems biology approaches in new cancer research programs O Wolkenhauer, C Auffray, S Baltrusch, N Blüthgen, H Byrne, M Cascante, ... Cancer research 70 (1), 12-13, 2010 | 45 | 2010 |
A mathematical model that accounts for the effects of caloric restriction on body weight and longevity IMM Van Leeuwen, FDL Kelpin, S Kooijman Biogerontology 3, 373-381, 2002 | 43 | 2002 |
Cyclotherapy: opening a therapeutic window in cancer treatment IMM van Leeuwen Oncotarget 3 (6), 596, 2012 | 39 | 2012 |
From exposure to effect: a comparison of modeling approaches to chemical carcinogenesis IMM van Leeuwen, C Zonneveld Mutation Research/Reviews in Mutation Research 489 (1), 17-45, 2001 | 36 | 2001 |